Strides Pharma Science Limited
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products f… Read more
Strides Pharma Science Limited (STAR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.060x
Based on the latest financial reports, Strides Pharma Science Limited (STAR) has a cash flow conversion efficiency ratio of 0.060x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹1.20 Billion) by net assets (₹19.94 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Strides Pharma Science Limited - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Strides Pharma Science Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Strides Pharma Science Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Strides Pharma Science Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningxia Western Venture Industrial Co Ltd
SHE:000557
|
0.016x |
|
Antin Infrastructure Partners
LSE:0AA5
|
0.415x |
|
A-Zenith Home Furnishings Co Ltd
SHG:603389
|
-0.230x |
|
Ronglian Group Ltd
SHE:002642
|
-0.030x |
|
Nexpoint Residential Trust Inc
NYSE:NXRT
|
0.089x |
|
Controladora Vuela Compañía de Aviación S.A.B. de C.V
MX:VOLARA
|
0.782x |
|
SUN COUNTRY AIRL.HLD.-01
F:6X2
|
N/A |
|
NOS S.G.P.S. S.A
PINK:ZONNF
|
0.163x |
Annual Cash Flow Conversion Efficiency for Strides Pharma Science Limited (2005–2025)
The table below shows the annual cash flow conversion efficiency of Strides Pharma Science Limited from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹25.86 Billion | ₹6.84 Billion | 0.265x | -21.81% |
| 2024-03-31 | ₹20.72 Billion | ₹7.01 Billion | 0.338x | +1555.68% |
| 2023-03-31 | ₹21.73 Billion | ₹444.11 Million | 0.020x | +118.89% |
| 2022-03-31 | ₹23.83 Billion | ₹-2.58 Billion | -0.108x | -163.23% |
| 2021-03-31 | ₹28.14 Billion | ₹4.81 Billion | 0.171x | +116.77% |
| 2020-03-31 | ₹25.95 Billion | ₹2.05 Billion | 0.079x | +268.20% |
| 2019-03-31 | ₹28.02 Billion | ₹600.55 Million | 0.021x | -70.10% |
| 2018-03-31 | ₹26.09 Billion | ₹1.87 Billion | 0.072x | -28.48% |
| 2017-03-31 | ₹28.74 Billion | ₹2.88 Billion | 0.100x | +306.53% |
| 2016-03-31 | ₹29.06 Billion | ₹716.57 Million | 0.025x | -65.60% |
| 2015-03-31 | ₹11.64 Billion | ₹834.00 Million | 0.072x | +135.70% |
| 2014-03-31 | ₹10.82 Billion | ₹-2.17 Billion | -0.201x | -413.53% |
| 2013-03-31 | ₹20.98 Billion | ₹1.34 Billion | 0.064x | -80.13% |
| 2012-03-31 | ₹14.18 Billion | ₹4.57 Billion | 0.322x | +54.77% |
| 2011-03-31 | ₹15.55 Billion | ₹3.24 Billion | 0.208x | +255.34% |
| 2010-03-31 | ₹10.90 Billion | ₹638.65 Million | 0.059x | -70.36% |
| 2009-03-31 | ₹5.96 Billion | ₹1.18 Billion | 0.198x | -41.18% |
| 2008-03-31 | ₹2.94 Billion | ₹987.01 Million | 0.336x | +34.31% |
| 2007-03-31 | ₹4.31 Billion | ₹1.08 Billion | 0.250x | +9.80% |
| 2006-03-31 | ₹3.47 Billion | ₹790.26 Million | 0.228x | -33.74% |
| 2005-03-31 | ₹2.18 Billion | ₹749.22 Million | 0.344x | -- |